October 17, 2019 10:32 AM EDT
News Briefing

Af­ter 13% dis­count In­nate Phar­ma rais­es $69M; AZTher­a­pies bags $26.3M from Se­ries C fi­nanc­ing round

Kathy Wong

Editor

→ As­traZeneca-part­nered French biotech In­nate Phar­ma — which was shoot­ing for a $100 mil­lion IPO by of­fer­ing 10.7 mil­lions shares at $7.50 per share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times